PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Cancer Discov. Author manuscript; available in PMC 2014 May 1.
Published in final edited form as:
PMCID: PMC3651770
NIHMSID: NIHMS453227

TYK2-STAT1-BCL2 Pathway Dependence in T-Cell Acute Lymphoblastic Leukemia

Abstract

Targeted molecular therapy has yielded remarkable outcomes in certain cancers, but specific therapeutic targets remain elusive for many others. As a result of two independent RNA interference (RNAi) screens, we identified pathway dependence on a member of the JAK tyrosine kinase family, TYK2, and its downstream effector STAT1 in T-cell acute lymphoblastic leukemia (T-ALL). Gene knockdown experiments consistently demonstrated TYK2 dependence in both T-ALL primary specimens and cell lines, and a small-molecule inhibitor of JAK kinase activity induced T-ALL cell death. Activation of this TYK2-STAT1 pathway i n T-ALL cell lines occurs by gain-of-function TYK2 mutations or activation of IL-10 receptor signaling, and this pathway mediates T-ALL cell survival through upregulation of the anti-apoptotic protein BCL2. These findings indicate that in many T-ALL cases, the leukemic cells are dependent upon the TYK2-STAT1-BCL2 pathway for continued survival, supporting the development of molecular therapies targeting TYK2 and other components of this pathway.

Keywords: Tyrosine kinase, TYK2, STAT1, BCL2, T-ALL

INTRODUCTION

Tyrosine kinase abnormalities are widely implicated in the genesis of human cancers (1). Although small-molecule tyrosine kinase inhibitors have produced remarkable clinical results against certain malignancies (2-5), the impact of such therapy has been restricted by our lack of knowledge of the pathogenic tyrosine kinases and associated signaling pathways that are required by malignant cells for continued survival and proliferation (“pathway dependence”). This deficit is especially apparent in T-cell acute lymphoblastic leukemia (T-ALL), which results from the leukemic transformation of thymic T-cell precursors and shows resistance to first-line therapy in 25% of children and more than 50% of adults (6, 7). A variety of genetic lesions have been identified in T-ALL, including aberrant expression of TAL1, LYL1, TLX1/HOX11 and TLX3/HOX11L2 (8, 9), activating mutations of NOTCH1 (10), and genomic duplication of MYB (11), but so far these advances have led to relatively few candidates for molecularly targeted therapies to improve remission rates or survival for patients with this disease.

The pro-survival members of the BCL2 family as well as pathways that signal upstream of these proteins are attractive candidate targets in T-ALL, since these proteins are known to determine whether developing T-cells undergo apoptosis in the thymus or survive to reach peripheral organs (12, 13). Normally, thymocytes will only survive to maturity if they can productively rearrange their T-cell receptors (TCRs) such that they react with foreign antigens and do not react with “self” antigens. In contrast, the vast majority of thymocytes that fail to rearrange their TCRs in this manner are eliminated by activation of pro-apoptotic BCL2 family members followed by Caspase-mediated cell death. Defective signaling through this pathway would enable thymocytes slated for destruction to survive and acquire additional lesions that promote full malignant transformation. This suggests that T-ALL cells may have acquired a dependence on this specific pathway whose actions perturb the normal balance between thymocyte life or death signaling cues.

Here we identify pathway dependence in T-ALL on the aberrant activation of tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family that phosphorylates and activates STAT1 and leads to the upregulation of BCL2, which is then required for T-ALL cell survival.

RESULT

Loss-of-function RNAi Screens

To understand the oncogenic contribution of tyrosine kinases in T-ALL, we performed an RNAi Assisted Protein Target Identification (RAPID) screen of primary leukemic cells from a pediatric T-ALL patient, applying validated siRNAs to silence each member of the tyrosine kinome (14). The result showed clear dependence of these leukemic cells on the TYK2 tyrosine kinase for their viability (Fig. 1A and Supplementary Table 1). We independently performed an RNAi screen in which 5,000 inducible short-hairpin RNAs (shRNAs) targeting 1,740 genes (15, 16) were introduced into three T-ALL cell lines (JURKAT, CCRF-CEM and SKW-3/KE-37). By determining the relative abundance of each shRNA in shRNA-induced versus uninduced samples after 3 weeks of induction, we identified shRNAs that were significantly depleted in T-ALL cell lines (Supplementary Table 2). Notably, an shRNA targeting TYK2 was depleted from cultures of these T-ALL cell lines (Fig. 1B), indicating that this gene is required for T-ALL cell survival or proliferation, while control diffuse large B-cell lymphoma cells showed little to no depletion of cells harboring TYK2-specific shRNA.

Figure 1
TYK2 is required for the survival of T-ALL cells

We then asked whether this activity was restricted to TYK2 or might be shared with other members of the JAK family tyrosine kinases. By testing multiple lentiviral shRNA constructs targeting JAK1, JAK2, JAK3 or TYK2 in JURKAT cells (Supplementary Fig. 1 and Supplementary Table 3), we found that knockdown of TYK2, but not of other JAK family genes, reduced cell growth (Fig. 1C), indicating that the cells specifically depend on TYK2 within the JAK family kinases. Significantly, we observed growth inhibition for each of the three independent shRNAs in a long-term culture (Fig. 1D). After analyzing additional T-ALL cell lines, we found that the growth of 14 (88 %) of 16 successfully transduced cell lines was significantly inhibited after silencing of TYK2 (“TYK2-dependent” cells), while two others (LOUCY and TALL-1) were unaffected (“TYK2-independent” cells)(Supplementary Table 4). Representative results with five cell lines are shown in Fig. 1E. To further explore TYK2 dependence in primary T-ALL specimens, we transfected TYK2 or control siRNA ex vivo into leukemic cells derived from T-ALL patients that had been directly expanded in immunocompromised mice (“primagraft” samples). We found that five (62.5%) of eight primagraft samples (#1-5) showed sensitivity to silencing of TYK2 (Fig. 1F). These results indicate that a significant fraction of T-ALL cells from human patients depend on TYK2 for sustained growth.

To determine the mechanism(s) underlying the impaired cell growth observed after TYK2 silencing, we stained cells with Annexin V and found increased percentages of apoptotic cells in the TYK2-dependent cell lines JURKAT, RPMI-8402 and HPB-ALL but not in the TYK2-independent cell line LOUCY (Fig. 1G). TYK2 knockdown had little effect on cell cycle distribution (Supplementary Fig. 2), indicating that the T-ALL cells primarily require TYK2 for survival rather than proliferation. Expression of the cDNA containing only the coding region of wild-type TYK2 rescued the JURKAT cells from apoptosis (Fig. 1H, left panel, as indicated by PARP cleavage) and growth inhibition (right panel), confirming that shRNA targeting TYK2 induces apoptosis due to its silencing of TYK2 and not to any off-target effects.

TYK2 Pathway Includes STAT1 and BCL2

Based on our results implicating TYK2 signaling as essential for T-ALL cell survival, we investigated downstream mediators of the TYK2 pathway. STAT1 is an attractive candidate effector of TYK2 signaling, as STAT1 is phosphorylated on tyrosine and activated downstream of TYK2 activation in cytokine signaling pathways such as the IL-10 pathway (Fig. 2A)(17). Indeed, tyrosine phosphorylation of STAT1 was observed in 16 of 19 T-ALL cell lines, most of which were TYK2-dependent (Supplementary Table 4), whereas tyrosine phosphorylation of STAT2, for example, was not observed (Supplementary Fig. 3A). STAT1 was also phosphorylated in the LOUCY and TALL-1 TYK2-independent cell lines, presumably due to activation by other pathways, indicating that these cell lines do not depend on the TYK2 pathway for survival. Further investigation showed that silencing of endogenous TYK2 resulted in decreased STAT1 phosphorylation in JURKAT cells, whereas overexpression of wild-type TYK2 caused increased STAT1 phosphorylation (Fig. 2B). We also observed constitutive phosphorylation of STAT3 in many T-ALL cell lines (Supplementary Fig. 3), although knockdown or overexpression of TYK2 did not change the phosphorylation status of STAT3 (Fig. 2B). STAT5 phosphorylation has been associated with other genetic abnormalities, such as mutation of the IL-7R (DND-41)(18), NUP214-ABL fusion (ALL-SIL and PEER)(19) and LCK-TCR fusion (H-SB2)(20); whereas AKT phosphorylation has been mostly associated with deletion/mutation of the PTEN gene (21). Phosphorylation of ERK1/2 was detected only in some cell lines. Importantly, knockdown of STAT1 decreased the growth of each of two TYK2-dependent cell lines (JURKAT and HPB-ALL) but not that of the LOUCY TYK2-independent cell line (Fig. 2C and Supplementary Fig. 4A). Thus, STAT1 appears to be a component of the TYK2-mediated pathway that promotes cell survival in T-ALL. This activity stands in marked contrast to type-I interferon signaling through TYK2, which leads to tyrosine phosphorylation of both STAT1 and STAT2 (Supplementary Fig. 3B).

Figure 2
TYK2-STAT1 pathway upregulates the anti-apoptotic protein BCL2 in T-ALL

To identify the effector molecules downstream of the TYK2-STAT1 pathway in T-ALL, we analyzed global gene expression profiles in JURKAT cells after silencing of TYK2 or STAT1. Gene set enrichment analysis (GSEA) revealed that a shared set of genes was downregulated after either TYK2 or STAT1 silencing (Fig. 2D). Importantly, we found that mRNA encoding the BCL2 anti-apoptotic protein was significantly downregulated after silencing of both TYK2 and STAT1 (Fig. 2E). Other anti-apoptotic BCL2 family proteins and IAP family proteins were not significantly downregulated after silencing of TYK2 or STAT1, and pro-apoptotic BCL2 family proteins were not upregulated after TYK2 knockdown (Supplementary Table 5). Analysis by quantitative PCR of additional T-ALL cell lines revealed that silencing of TYK2 resulted in significant reductions of BCL2 mRNA expression in multiple TYK2-dependent cell lines, but not in the LOUCY TYK2-independent T-ALL cell line (Fig. 2F), which appears to have constitutively upregulated BCL2 through a pathway independent of TYK2. Expression of wild-type but not kinase-dead TYK2 (M978F) protein was sufficient to rescue BCL2 protein expression and to prevent apoptosis after knockdown of endogenous TYK2 in the TYK2-dependent line (Figs. 2G and 2H). In fact, expression of the kinase-dead TYK2 protein repressed BCL2 expression (Fig. 2G) and increased baseline levels of apoptosis (Fig. 2H), suggesting that it could be interfering with residual endogenous TYK2 activity. Similarly, expression of the shRNA-resistant wild-type STAT1α protein partially rescued BCL2 protein expression (Fig. 2I) and prevented apoptosis (Fig. 2J), while STAT1α Y701F (which is incapable of being activated by phosphorylation) did not rescue BCL2 levels and caused increased levels of apoptosis. Taken together, these results demonstrate that TYK2 effects are in part mediated through STAT1, and that the TYK2-STAT1 pathway acts at least in part by upregulating BCL2 expression in T-ALL cells, thereby promoting their aberrant survival.

Activating TYK2 Mutations in T-ALL

To investigate the possibility that the TYK2 kinase might be mutationally activated, we sequenced the TYK2 coding regions in 17 T-ALL cell lines and 45 primary pediatric T-ALL patient samples (Supplementary Tables 6 and 7). This analysis identified novel non-synonymous sequence variants of TYK2 in four cell lines (21.1%), none of which represent known single nucleotide polymorphisms based on the dbSNP137 and the 1000 Genomes databases (22, 23). These included point mutations in the TYK2 FERM domain (G36D, S47N and R425H), the JH2 domain (V731I), and the kinase domain (E957D and R1027H) (Figs. 3A and 3B; and Supplementary Table 6). The functional consequence of each point mutation was then determined by testing its ability to transform IL-3-dependent murine pro-B Ba/F3 cells to cytokine-independent growth. We observed that expression of five of the six TYK2 cDNA mutants (G36D, S47N, V731I, E957D and R1027H) converted the Ba/F3 cells to IL-3-independent growth (Fig. 3C). Expression of the wild-type TYK2 did not transform Ba/F3 cells, nor did TYK2-R425H, suggesting that this sequence variant represents a rare SNP or a “passenger” mutation. Analysis of whole-cell extracts from Ba/F3 cells transformed by mutant TYK2 proteins showed a marked increase in TYK2 tyrosine phosphorylation (Fig. 3D, lanes 4-8) compared to that observed in wild-type TYK2-expressing cells starved of IL-3 (lane 3). There was also an increase in tyrosine phosphorylation of STAT1 (Fig. 3D). Overall levels of STAT1 were also increased in mutant TYK2-expressing cells, consistent with previous observations of STAT1 activation leading to enhanced nascent STAT1 expression (24). Expression of TYK2-V678F (equivalent of JAK2-V617F)(25), which induces constitutive activation of the TYK2 kinase, served as a positive control (Fig. 3D, lane 1). Importantly, introduction of the kinase-dead mutation (M978Y or M978F) into the TYK2 cDNA that also had an activating mutation (E957D) resulted in failure to transform Ba/F3 cells (Fig. 3E), confirming that kinase activity of TYK2 is required for cell transformation. Phosphorylation of each of the TYK2 and STAT1 proteins was also abrogated by introduction of the kinase-dead mutation into HEK293 cells (Fig. 3F). Finally, we tested the ability of the TYK2-E957D point mutant to promote the expansion of primary murine T-lineage cells in murine bone marrow cells plated on OP9 DL1 stromal cells. Transduction of TYK2-E957D together with GFP into bone marrow cells significantly fostered cell growth compared to the result for cells expressing an empty vector or wild-type TYK2 (Fig. 3G); flow cytometric analysis of the expanded cells confirmed the expression of both CD3 and GFP (Supplementary Fig. 5).

Figure 3
Activating mutations of TYK2 gene in T-ALL

TYK2 Pathway Activation by IL-10 Signaling

Mutations of the TYK2 gene provide a mechanism for aberrant TYK2 activation in some T-ALL cell lines; however, many T-ALL samples that were TYK2 dependent lacked mutations within this gene, implicating alternative mechanism(s) of kinase activation that drive pathway dependence. In the context of cytokine signaling, TYK2 is known to be activated by upstream receptors, including the type-I interferon (IFNα/β), I L-6, IL-10, IL-11, IL-12, IL-23 and IL-27 receptors (17, 26). Thus, we hypothesized that autocrine activation of one or more of these receptors might be responsible for activating the TYK2 pathway. Among the known cytokine pathways, autocrine IL-10 receptor signaling was an attractive possibility, because IL-10 has been reported to increase BCL2 expression and cell survival in hematopoetic progenitor cells (27), primary T-cells (28) and germinal center B-cells (29). To test this notion, we evaluated the effects on cell growth of shRNAs specific for the IL-10 and for IL-10R genes (IL10RA and IL10RB; Supplementary Fig. 4A), which are endogenously expressed in all cell lines examined (Supplementary Figs. 6A and 6B). In two T-ALL cell lines that are TYK2-dependent but without a mutation of the TYK2 gene (HPB-ALL and JURKAT), knockdown of IL-10, IL10RA or IL10RB resulted in a reduction of cell growth (Fig. 4A) and the induction of apoptosis (Fig. 4B), coincident with downregulation of BCL2 expression (Fig. 4C), indicating that IL-10 signaling is required for T-ALL cell survival. Of note, knockdown of other cytokine receptor genes (IFNAR1, IFNAR2, IL6ST, IL11RA, IL12RB1, IL12RB2 and IL27RA) did not downregulate BCL2 expression in T-ALL cells (Supplementary Fig. 4B). IL6R and IL23R, which encode other cytokine receptors that can interact with TYK2, were not expressed in T-ALL cell lines.

Figure 4
IL-10 receptor signaling is required for TYK2 activation and cell survival in T-ALL

Knockdown of the IL-10 receptor genes in these cell lines resulted in downregulation of STAT1 phosphorylation (Fig. 4D), indicating that the IL-10 receptor is required for activation of the TYK2-STAT1 pathway. Treatment of these cell lines with an anti-IL10-neutralizing antibody did not show any effects on cell growth (Supplementary Fig. 6C), suggesting that this pathway may be activated during intracellular trafficking of the ligand and receptor. By contrast, there was little or no effect on cell growth or survival when these shRNAs were introduced into the LOUCY TYK2-independent cell line. In MOLT-4 cells that harbor an activating TYK2 mutation (E957D), knockdown of the IL-10 receptor gene resulted in lower levels of BCL2 and induced apoptosis, suggesting that the IL-10 receptor proteins may still be required as a scaffold when the TYK2 protein is mutationally activated.

Pharmacologic Inhibition of TYK2

To assess the efficacy of JAK inhibitors for impairing the growth and viability of TYK2-dependent T-ALL cells, we chose three compounds (JAK inhibitor I, AG490 and CP-690550) with differing degrees of efficacy against TYK2 compared to other JAK family members. JAK Inhibitor I has been shown to exhibit potent activity against all JAK family kinases, including TYK2 (30). Indeed, Ba/F3 cells transformed by constitutively active JAK kinases (TYK2-E957D, TEL-JAK1, TEL-JAK2, and TEL-JAK3) were consistently sensitive to this inhibitor compared to a negative control Ba/F3 cell line transformed by an alternative tyrosine kinase, TEL-ABL (Fig. 5A). Further use of JAK Inhibitor I against T-ALL cell lines revealed that the TYK2-dependent cell lines were sensitive to this inhibitor, with IC50 values ranging from 1-3 μM, while a TYK2-independent cell line, LOUCY, was insensitive (Fig. 5B). In the JURKAT TYK2-dependent cells, the cell number was significantly lower in the inhibitor-treated sample than in the control after long-term treatment, whereas this effect was less pronounced in the LOUCY TYK2-independent line (Fig. 5C). A broader analysis of 19 T-ALL cell lines revealed a strong correlation between sensitivity to TYK2 shRNA and sensitivity to JAK kinase inhibitors (Supplementary Table 4). Treatment with AG490, a pan-JAK family inhibitor (31), yielded essentially the same results as JAK Inhibitor I (Supplementary Fig. 7A). By contrast, T-ALL cell lines treated with CP-690550, a potent inhibitor of JAK2 and JAK3 but not TYK2 (32), were resistant to this compound (Supplementary Fig. 7B). These results indicate that the sensitivity of T-ALL cells to JAK Inhibitor I and AG490 is not due to inhibition of JAK2 or JAK3, but to activity against TYK2, consistent with our initial findings using RNAi gene silencing techniques (Figs. 1A-C). Immunoblots of cell lysates after treatment with JAK Inhibitor I showed decreased phosphorylation of both TYK2 and STAT1 in the Ba/F3 cells expressing TYK2-E957D (Fig. 5D). Moreover, apoptosis was induced in TYK2-dependent lines after JAK inhibitor I treatment, as indicated by increased levels of Annexin V staining, which was not observed in the TYK2-independent LOUCY cells (Fig. 5E). Flow cytometric analysis of TYK2-dependent lines after treatment with JAK Inhibitor I showed an increase in the number of sub-G1 cells, consistent with ongoing apoptosis (Supplementary Fig. 8). We also observed an increase of G2/M fraction cells; however, these changes in the cell cycle were not apparent by shRNA TYK2 knockdown in the same cell lines (Supplementary Fig. 2). Further investigation will be required to determine whether this is a specific effect of inhibiting TYK2. Taken together, these results indicate that pharmacologic inhibition of TYK2 kinase activity induces the death of TYK2-dependent T-ALL cells.

Figure 5
Activity of small-molecule inhibitors of TYK2 against transformed Ba/F3 and T-ALL cells

Discussion

Our studies establish dependence on the TYK2-STAT1 pathway in 14/16 T-ALL cell lines and 5/8 primagraft samples. These findings are the first to implicate TYK2 activation in oncogenesis, and to show that the oncogenic TYK2 signaling pathway differs from previously described TYK2 signaling pathways, in which TYK2 and JAK1, as well as other JAK kinases, cross-activate one another. Porcu and colleagues reported that the HPB-ALL TYK2-dependent cell line expresses a different JAK1 transcript variant, which does not encode a critical portion of the kinase domain (33), suggesting selective pressure to inactivate the JAK1 kinase in T-ALL. Two other TYK2-dependent cell lines, MOLT-4 and RPMI-8402, express another JAK1 transcript variant that generates a truncated form of JAK1 protein lacking the entire kinase domain (33). Thus, inactivation of JAK1 kinase through mutation or alternative splicing may contribute to the non-canonical TYK2-mediated pathway that promotes cell survival in T-ALL. Alternatively, activating mutations of JAK1 have also been observed in some cases of T-ALL, mostly in adult patients —1/49 (2%)(34), 4/108 (4%)(35), 8/38 (21%)(34), and 3/11 (27%)(36). Hence, although activated JAK1 may contribute to T-ALL pathogenesis in some cases, in other T-ALL cases dependent on TYK2 signaling for cell survival there appears to be concomitant selective pressure to inactivate signaling molecules downstream of JAK1.

We found that the TYK2-STAT1 pathway positively regulates BCL2 expression in T-ALL cells, contributing to aberrant cell survival. It has been reported that mitochondria from chemosensitive cancer cells such as ALL are consistently more “primed”, so that the cells are prone to undergo apoptosis than are those from normal tissues (37). Leukemia cells require BCL2 in addition to other anti-apoptotic BCL2 family members to sequester pro-apoptotic proteins such as BIM, indicating that inhibition of BCL2 protein is a useful strategy to induce apoptosis in already “primed” leukemia cells. The fact that the ABT-737 BCL2 antagonist induces apoptosis in BCL2-overexpressing chronic lymphoid leukemia cells (38) supports this finding. Our results are consistent with the dependence of T-ALL cells that are “primed” to undergo apoptosis on upregulated levels of BCL2 expression induced by TYK2, and this model explains why the T-ALL cells die when TYK2 is silenced and BCL2 levels fall. BCL2 is normally not detectable in immature thymocytes in the thymic cortex but is markedly upregulated in more mature single-positive T-cells that migrate into the thymic medulla (12, 39), thereby enabling functionally-selected thymocytes to survive. This anti-apoptotic protein is also frequently overexpressed in T-ALL as well as in T-cell lymphoblastic lymphoma (T-LBL), a distinct clinical presentation of thymocyte malignancy (39). Of note, in Tyk2 knockout mice (40), blood cell counts and thymic morphology and size are all normal (41) and there is no difference in Bcl2 protein expression in the thymus between Tyk2 knockout and wild-type mice (Supplementary Fig 9). Thus, TYK2 is not required for the upregulation of BCL2 expression by normal medullary thymocytes, but its aberrant gain-of-function activity in immature double-positive T-ALL/T-LBL cells can nevertheless promote BCL2 overexpression and aberrant cell survival, leading to clonal expansion of fully transformed leukemic lymphoblasts.

Our work indicates that in a subset of T-ALLs lacking TYK2 activating mutations, the TYK2 pro-survival pathway could be activated downstream of autocrine activation of IL-10 and its receptors. IL-10 is a multifunctional cytokine with pleiotropic effects on different hematopoietic cells types (42). IL-10 signaling is primarily involved in limiting or terminating inflammatory responses, at least in part by promoting the activity of regulatory T-cells. In other contexts, IL-10 has been shown to enhance the survival of hematopoetic stem cells, B-cells, T-cells and tumor cells (27-29) through its ability to upregulate BCL2. The IL-10 ligand-receptor interaction normally engages both JAK1 and TYK2, which are constitutively associated with IL-10RA and IL-10RB, respectively. In T-ALLs that depend on TYK2 activity for cell survival, we determined that JAK1 activity is not required (Figs. 1A-C), and in some of these cases, JAK1 is actually inactivated by mutation or alternative splicing (33), suggesting a non-canonical independent role for TYK2 in the aberrant survival of T-ALL cells.

We hypothesize that autocrine expression of IL-10 or rarely TYK2-activating mutations are acquired during thymocyte transformation, presumably at the point when mitochondria have become “primed” due to cooperating oncogenic mutations so that the cells are prone to undergo apoptosis (37). Our study has identified dependence on TYK2 kinase activity as a requirement for the survival of a substantial fraction of human T-ALL cell lines and primagraft T-ALL samples. This discovery adds a novel mechanism to the repertoire by which cancer cells block pathways leading to cell death in particular lineages. Indeed, the promotion of tumor cell survival is now an established step in the molecular pathogenesis of human cancers, including leukemias, which is distinct from changes leading to the initiation, repopulation, self-renewal or proliferation of transformed cells. Unless apoptosis is blocked, and the emerging precancerous clone is able to survive, it will not be possible for the evolving malignant cells to select for additional mutations and acquire a fully transformed phenotype.

Our study also demonstrates that pharmacologic inhibition of TYK2 kinase activity induces the death of TYK2-dependent T-ALL cells, which combined with TYK2 knockdown experiments, indicates dependence on the TYK2-STAT1 pathway. A clear implication of these results is that drugs able to potently inhibit TYK2 are likely to provide a therapeutic advantage in patients with T-ALL. A loss-of-function mutation in the TYK2 gene was identified in a patient with hyperimmunoglobulin E syndrome (43), a primary immunodeficiency characterized by elevated serum immunoglobulin E, which in this case was associated with an increased susceptibility to infection by various microorganisms. These findings support the notion that TYK2 inhibition would not have a significant effect on the development of normal T-cells or these precursors or hematopoietic stem/progenitor cells, although it might cause susceptibility to viral infections after prolonged exposure. The only effective inhibitor of TYK2 that we have identified is JAK Inhibitor I, a “tool” compound that remains suboptimal for use in patients. Unfortunately, the JAK kinase inhibitors now in clinical use were developed against alternative JAK kinases, so are not potent inhibitors of TYK2. Hence, there is a need to identify potent new drugs with tolerable side effects that could be used to target TYK2 in T-ALL cells dependent on this kinase.

Materials and Methods

Collection of Primary T-ALL Specimen

For RAPID assay, T-ALL diagnostic specimens were collected with informed consent and institutional review board (IRB) approval of Oregon Health & Science University. Bone marrow cells from patients were separated on a Ficoll gradient, and mononuclear cells were treated with ACK lysis buffer. For TYK2 genotyping, T-ALL diagnostic specimens were collected with informed consent and IRB approval of Dana-Farber Cancer Institute (clinical trial 00-001) and Children’s Oncology Group (clinical trial 9404; Clinicaltrials.gov identifier: NCT00165178). For the primagraft experiment, diagnostic T-ALL patient samples were obtained with informed consent and IRB approval of Dana-Farber Cancer Institute study 05-01, BC Cancer Agency (BCCA) study H06-00028, and were used with IRB approvals by the University of California, San Diego (UCSD) Human Research Protections Program and BCCA.

Primagrafts

Mice studies were carried out in strict accordance with the recommendations of the Institutional Animal Care and Use Committee (IACUC), and the protocols were approved by the Committee at the UCSD (Protocol S06015) and the University of British Columbia (Protocol A09-0771). T-ALL diagnostic specimens were transplanted into Rag2−/−γc−/− or NOD/Scid/Il2rg−/− (NSG) mice to propagate the cells as “primagrafts”. Mononuclear cells were purified by Ficoll-Hypaque centrifugation prior to FACS analysis and viable cryopreservation in liquid nitrogen. Approximately 50,000 human CD34+ cells selected from above T-ALL samples with the aid of FACSAria II (BD Biosciences) or immunomagnetic beads (Miltenyi Biotec) were transplanted intrahepatically into Rag2−/−γc−/− neonatal mice within 48 hrs of birth. Mice were sacrificed at eight weeks after transplantation. Bone marrow (BM), spleen, thymus, liver and peripheral blood was collected for FACS analysis of human CD45, CD34, CD2, and CD7 expressions. Serial transplantation was done by intrahepatically injecting 50,000 human CD34+ cells selected from the T-ALL primary engrafted BM or thymus into the neonatal Rag2−/−γc−/− mice to propagate the cells. NSG primagrafts performed at BCCA were performed by injection of 1-2×106 unsorted patient BM cells either IV (tail vein) or IF (femur) into sublethally irradiated adult recipient NSG mice. Human leukemia cells were harvested from BM and spleen of morbid animals and characterized by FACS and/or TCRγ HDA clonality assay, as previously described (44).

Cell Culture

All T-ALL cell lines were stocked in our laboratory and were confirmed by DNA fingerprinting using the PowerPlex 1.2 system (Promega) in January 2013. HEK293T and Ba/F3 cells were recently obtained from American Type Culture Collection (Manassas, VA). HEK293T17 cells were kindly provided by Dr. Richard Van Etten (Tufts-New England Medical Center, Boston, MA). Ba/F3 derivatives expressing various oncogenic fusion kinases, namely, TEL-JAK1, TEL-JAK2, TEL-JAK3 and TEL-ABL, were obtained from Dr. Richard Moriggl and were described previously (45). T-ALL cells were maintained in “R10” (RPMI-1640 medium supplemented with 10% FBS, L-glutamine and penicillin/streptomycin; Invitrogen. Ba/F3 cells were maintained in R10 supplemented with 15% WEHI-conditioned media. HEK293T17 cells were maintained in DMEM medium supplemented with 10% FBS, L-glutamine, penicillin/streptomycin and fungizone.

RNAi Assisted Protein Target Identification (RAPID) Screen

The RAPID screen was performed as previously described (46, 47). Briefly, primary T-ALL cells (2.25 × 107) were washed in PBS (Invitrogen) and resuspended in 4.2 ml of siPORT buffer (Ambion). Cells were aliquoted at 42 μl per well onto a 96-well electroporator (Ambion), and 2 μl of siRNA at 20 μM was added to each well (tyrosine kinase library purchased from Dharmacon/Thermo Fisher Scientific). Single and pooled non-specific siRNA as well as siRNA against EPHA5, EPHA6, src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation (SRMS), apoptosis-associated tyrosine kinase (AATK), LMTK3, N-RAS, K-RAS (all from Dharmacon) were added separately because they are not included in the tyrosine kinase library. Cells were electroporated at 1110 V (equivalent of 150 V per well), 200 μsec, 2 pulses, and 50,000 cells per well were replated into triplicate plates containing 100 μl per well of culture media [RPMI-1640 supplemented with 20% FBS, L-glutamine, penicillin/streptomycin, fungizone, 1× insulin-transferrin-sodium selenite (Invitrogen), and 10−4 M 2-mercaptoethanol (Sigma-Aldrich)]. For determination of cell viability, cells were subjected to the CellTiter 96 AQueous One solution cell proliferation assay (MTS) (Promega). All values were normalized to the median value on the plate.

Inducible shRNA Screen

Inducible shRNA screen was performed as previously described (15, 16). Briefly, T-ALL cell lines were first transduced with an ecotropic retrovirus receptor. The host cells were then transduced with the tetracycline repressor gene and separated into single clones. Ecotropic retrovirus library was made by cotransfection of 1,000 retrovirus constructs into HEK293T cells with pHIT/EA6x3* and pHIT60 plasmids. Each T-ALL cell line was infected with each of five retrovirus pools (1,000 shRNAs/pool) separately in biological quadruplicate, selected by puromycin, divided into two groups and cultured with or without doxycycline for three weeks to induce shRNA. Genomic DNAs were then harvested and bar-code sequences amplified by PCR. Samples from the shRNA-induced cells and the matched uninduced cells were labeled with Cy3 or Cy5, respectively, and hybridized onto the microarray chip for quantitation of their relative abundance in each population. P-values were determined by paired t-test and adjusted for multiple comparisons; shRNA depletion (uninduced/induced) was then calculated for each shRNA. The shRNAs that are significantly depleted [adjusted p-value < 0.1, and shRNA depletion ≥ 0.585 (log2)] in T-ALL cell lines are selected (Supplementary Table 2).

Individual shRNA and siRNA Knockdown Analysis

All shRNA constructs cloned into the lentiviral vector pLKO.1-puro were obtained from the RNAi consortium (Broad Institute, Cambridge, MA). Each construct was co-transfected into HEK293T cells with packaging plasmid delta 8.9 and envelope plasmid VSV-G using FuGENE 6 reagent (Roche). Supernatants containing the lentivirus were collected and filtered through a 0.45 μm cellulose acetate membrane filter. T-ALL cells were infected with lentivirus in the presence of polybrene (8 μg/ml) and HEPES (10 mM) by centrifugation at 2,500 rpm for 1.5 h at 30°C, and the infected cells were selected by puromycin for at least 36 h. For siRNA primagraft studies, primagraft cells that were expanded in Rag2−/−γc−/− or NSG mice and subsequently on OP9-DL1 or MS5-DL1 co-culture were freshly harvested, washed with PBS, and incubated with non-specific (control) or TYK2 siRNA in siPORT buffer (Ambion). Cells were electroporated at 200 volts, 0.2 milliseconds for two pulses and then replated in culture media [RPMI-1640 supplemented with 20% FBS, L-glutamine, penicillin/streptomycin, fungizone, 1× insulin-transferrin-sodium selenite (Invitrogen), and 10-4 M 2-mercaptoethanol (Sigma-Aldrich)].

Cell Viability, Apoptosis Assays and Reagents

For siRNA knockdown experiment, cells were subjected to the CellTiter 96 AQueous One solution cell proliferation assay (Promega). All values were normalized to the mean of control siRNA cell viability values for each sample. For shRNA knockdown experiment, cells were subjected to the CellTiter Glo assay (Promega). For drug treatment, cells were incubated in the presence of graded doses of JAK Inhibitor I (EMD Biosciences) for 72 hrs. The number of viable cells was determined with the CellTiter 96 AQueous One solution cell proliferation assay (Promega). For determination of factor-independent growth, Ba/F3 cells were washed three times in R10, and 1 million cells were seeded into triplicate flasks in 2 ml of R10. Total viable cells were determined every day for 16 days using PI exclusion on a Guava cell counter (Guava Technologies). To analyze apoptosis, we washed the cells with PBS, incubated in staining buffer containing FITC-conjugated anti-Annexin V antibody (MBL International) and analyzed by BD FACSCalibur (BD Biosciences). For the rescue study, we used a PE-conjugated Annexin V antibody (MBL International), because the cells had been transduced with GFP as a selection marker for generation of a cell line that overexpresses TYK2.

Immunoblotting

T-ALL cell lines were lysed in RIPA buffer [50 mM Tris (pH8.0), 10 mM EDTA, 150 mM NaCl, 0.5% deoxycholic acid, 0.1% SDS, 1% NP-40] with phosphatase inhibitors (1 mM sodium pyrophosphate, 1 mM sodium orthovanadate) and protease inhibitors [protease inhibitor cocktail (Roche), 1 mM PMSF]. Ba/F3 and HEK293T17 cells were lysed in 1 × lysis buffer (Cell Signaling Tech). Equivalent amounts of protein were diluted in sample buffer (75 mM Tris pH 6.8, 3% SDS, 15% glycerol, 8% β-mercaptoethanol, 0.1 % bromophenol blue) and separated by SDS-PAGE. Proteins were transferred to PVDF membranes (Millipore) and subjected to immunoblot analysis with antibodies specific for TYK2, phospho-TYK2 (Y1054/1055), STAT1, phospho-STAT1 (Y701), STAT3, phospho-STAT3 (Y705), STAT5, phospho-STAT5 (Y694), ERK1/2, phospho-ERK1/2 (T202/Y204), PARP, α-tubulin (Cell Signaling Tech), or β-actin (Millipore).

Microarray Gene Expression Analysis and Gene Set Enrichment Analysis (GSEA)

JURKAT cells were transduced with control shRNA or shRNA targeting TYK2 or STAT1 in biological duplicate. Total RNA was harvested by Trizol followed by a column purification using the RNeasy Mini kit (Qiagen). A total of 12 RNA samples (4 controls, 4 TYK2 knockdown, 4 STAT1 knockdown) were used for microarray expression analysis. Genome-wide RNA expression analysis was performed by HG U133 plus 2.0 microarray chip (Affymetrix) at the Dana-Farber Cancer Institute. Expression data can be found at http://www.ncbi.nlm.nih.gov/geo/ under accession number GSE44652. After normalization using dChip (Dana-Farber Cancer Institute)(48), 30,988 probes with presence-call >33% (4/12 arrays) were filtered. The genes differentially expressed between 4 control and 4 knockdown samples were selected based on a lower 90% confidence bound of fold-change >1.4, P-value <0.05 by two sample t-test (two-tailed) and mean difference >50, by which the 90th percentile false discovery rates by 1,000 permutations were 1.1% (for TYK2 knockdown) and 1.9% (for STAT1 knockdown). GSEA (Broad Institute, Cambridge, MA) was performed by comparing 4 control samples with 4 knockdown samples. The genes that were significantly downregulated upon TYK2 or STAT1 knockdown were defined as described above and used as gene sets.

Quantitative RT-PCR Analysis

Total RNA from T-ALL cell lines was harvested by RNeasy (Qiagen) after three days of shRNA lentivirus infection, and transcribed to cDNA by Quantitect (Qiagen). Quantitative PCR analysis was performed by AB 7300 system (Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied Biosystems) and specific primers for each gene (Supplementary Table 8).

Cloning of Mutant STAT1 Construct and Rescue Study

The retrovirus construct encoding the mutant STAT1α (Y701F) cDNA as well as GFP, pMSCV-NP-hSTAT1-Y701F-FLAG, was obtained from Dr. Richard Moriggl. In order not to be recognized by STAT1 shRNA #3 that targets the coding region of STAT1, three point mutations (“wobble-base” mutations) were introduced with the Quikchange Lightning mutagenesis kit (Stratagene/Agilent Tech) using the following mutagenesis primers: forward, 5′-CGG ATA GTG GGC TCT GTA GAA TTT GAT AGC ATG ATG AAC ACA GTA GAC T-3′; reverse, 5′-AGT CTA CTG TGT TCA TCA TGC TAT CAA ATT CTA CAG AGC CCA CTA TCC G -3′. To make the wild-type STAT1α construct with three wobble-base mutations, Y701F mutation was repaired using the following mutagenesis primers: forward, 5′-GGC CCT AAA GGA ACT GGA TAT ATC AAG ACT GAG TTG ATT-3′; reverse, 5′-AAT CAA CTC AGT CTT GAT ATA TCC AGT TCC TTT AGG GCC-3′. Each construct was co-transfected into HEK293T cells with packaging plasmid pMD-MLV and envelope plasmid VSV-G using FuGENE 6 reagent (Roche). Supernatants containing the retrovirus were collected and filtered through a 0.45 μm cellulose acetate membrane filter. T-ALL cells were then infected with retrovirus in the presence of polybrene (8 μg/ml) and HEPES (10 mM) by centrifugation at 2,500 rpm for 1.5 h at 30°C. GFP-positive cells were sorted by FACSAria (BD Biosciences), and the single clone which expresses the same amount of exogenous STAT1α protein as the endogenous one was selected and infected with lentivirus encoding STAT1 shRNA #3.

Cloning of Mutant TYK2 Genes and Creation of Stable Ba/F3 Clones

For cloning of TYK2, cDNA was purchased from Origene and cloned into the EcoRI site of MSCV-IRES-GFP (MIG). Point mutations were introduced with the Quikchange XL-II mutagenesis kit (Stratagene/Agilent Tech). Retrovirus expressing TYK2-WT, TYK2-V15A, TYK2-G36D, TYK2-S47N, TYK2R-425H, TYK2-V731I, TYK2-E957D, TYK2-R1027H, TYK2-E957D/M978Y, or TYK2-E957D/M978F was propagated in HEK293T17 cells by co-transfection of each respective TYK2 construct with the EcoPak plasmid (kindly provided by Dr. Richard Van Etten) using FUGENE 6 (Roche). One milliliter of viral supernatant was mixed with polybrene (5 μg/ml), HEPES (7.5 mM), and 1 × 106 Ba/F3 cells and placed in a centrifuge at 2,500 rpm for 1.5 h at 30°C. GFP-positive cells were sorted on a FACSAria (BD Biosciences) after 48 h of infection.

Transient TYK2 Expression in HEK293T17 Cells

Constructs (MSCV-IRES-GFP) expressing TYK2-E957D, TYK2-E957D/M978Y, or TYK2-E957D/M978F were transfected into HEK293T17 cells using FUGENE 6 (Roche). After 48 hrs, cells were lysed and whole cell extracts were subjected to immunoblot analysis as described above.

Primary T-lineage Outgrowth Assay

Murine bone marrow cells were harvested from 6-week old C57BL/6 mice (The Jackson Labs, Bar Harbor, ME) and infected with two rounds of MIG retrovirus expressing empty vector, TYK2-WT, or TYK2-E957D as previously described (49). GFP-positive cells were sorted on a FACSAria (BD Biosciences) and plated into triplicate wells of 24-well plates (105 cells per well) that had been seeded with OP9-DL1 cells (kindly provided by Dr. Juan-Carlos Zúñiga-Pflücker, University of Toronto, Sunnybrook Research Institute, Toronto, Ontario, Canada). Cells were co-cultured in α-MEM media supplemented with 20% FBS, L-glutamine, penicillin/streptomycin, IL-7 (10 ng/ml), and FLT3 ligand (10 ng/ml) (Peprotech). Viable cells from each well were counted every 2 days by PI exclusion on a Guava cell counter. Wells containing only OP9-DL1 cells without bone marrow cells were also counted and these numbers were subtracted from total viable cells in co-culture wells (most OP9-DL1 cells could be gated out by forward scatter). All numbers were normalized to the cell counts obtained after 2 days of culture to control for minor differences in seeding density of cells. At the end of the experiment, outgrowth cells were stained with an antibody specific for CD3 (BD Biosciences) and analyzed on a FACSAria (BD Biosciences).

Sequencing Analyses

Genomic DNA from patient samples and cell lines was prepared by DNeasy (Qiagen) and used to sequence TYK2 gene (Genewiz, South Plainfield, NJ) using previously described primers (50).

Statistical Analyses

For RAPID functional screens, we calculated the mean cell viability for all data points. Values that were greater than two standard deviations from the mean were considered significant. For cell proliferation and viability assays, a difference in treatment, dose, or time point compared with the relevant control treatment or the no drug control was determined by analysis with a student’s t-test. IC50 values with a small-molecule inhibitor for each cell line were calculated by non-linear regression using GraphPad Prism software.

SIGNIFICANCE

In recent years, “pathway dependence” has been revealed in specific types of human cancer, which can be important because they pinpoint proteins that are particularly vulnerable to anti-tumor targeted inhibition (so-called “Achilles heel” proteins). Here we use RNAi technology to identify a novel oncogenic pathway that involves aberrant activation of the TYK2 tyrosine kinase and its downstream substrate, STAT1, which ultimately promotes T-ALL cell survival through the upregulation of BCL2 expression.

Supplementary Material

10

12

Acknowledgements

We gratefully acknowledge the children with T-ALL and their families, Drs. Stuart S. Winter, Richard S. Larson, Stephen Hunger, Lewis B. Silverman and Stephen E. Sallan, as well as members of the Oregon Health & Science University, Children’s Oncology Group and Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium, for the samples analyzed in these studies. We also acknowledge the RNAi Consortium for providing lentivirus shRNA constructs. We thank Dr. V. Penard-Lacronique for providing us with the TEL-fusion constructs used in the Ba/F3 cell experiments and Dr. Dong-Er Zhang for suggesting the possibility of TYK2 activation by autocrine signaling. We thank Mr. John R. Gilbert for critical review of the manuscript and helpful editorial suggestions.

Financial Supports: This work was supported in part by the William Lawrence and Blanche Hughes Fund, the Leukemia & Lymphoma Society, and the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. J.W.T. is supported by grants from the National Cancer Institute (4R00CA151457-03) and the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 from the National Center for Research Resources (NRCC), a component of the NIH, and the NIH Roadmap for Medical Research. T.S. is supported by NIH grant NCI 1K99CA157951, Children’s Leukemia Research Association and the Japan Society for the Promotion of Science. A.G. is supported by NIH grant NCI 1K08CA133103 and is a scholar of the American Society of Hematology-Amos Medical Faculty Development Program. B.H.C is supported by the Oregon Child Health Research Center and is a St. Baldrick’s Scholar. R.M. and M.M. are supported by grant SFB F28 of the Austrian Science Fund FWF. A.T.L and D.S.N. are supported by NCI grants 5P01CA109901 and NCI 5P01CA68484, and A.T.L. is by an Alex’s Lemonade Stand Foundation Bridge grant. B.J.D. is an investigator of the Howard Hughes Medical Institute and principal investigator of the OHSU cancer center support grant 5P30CA069533. M.K. is supported by the European Molecular Biology Organization (EMBO) long-term fellowship. R.L.L. is a Scholar of the Leukemia and Lymphoma Society. A.Y. and A.P.W. are supported by a CIHR/Terry Fox Foundation program project grant. W.M. and C.H.M.J. are supported by the California Institute for Regenerative Medicine (CIRM) grants (TR21789; RN2-00910-1; DR1-01430), as well as the Leichtag family foundation and the Ratner family foundation.

Footnotes

Disclosure of Potential Conflicts of Interest:

No potential conflicts of interest were disclosed by all authors.

Author’s Contributions

T.S, J.W.T, B.J.D and A.T.L. designed the experiments and wrote the manuscript. T.S., J.W.T., A.G.F. and R.M. carried out the functional analyses; A.G., J.G. and B.H.C. provided and analyzed the patient samples; A.Y., W.M., J.T., M.A.K., C.H.M.J and A.P.W. provided primagraft samples; V.N.N., Y.Y., Y.A. and L.M.S. performed RNAi screens; Y.Y. and D.S.N. performed the statistical analyses; W.Z. and N.S.G. performed the homology modeling; R.M. and M.M. analyzed Tyk2 knockout mice. M.K. measured cytokine expression levels in T-ALL cell lines. R.M., M.M., R.L.L. and L.M.S. provided advice on the manuscript.

References

1. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–87. [PubMed]
2. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17. [PubMed]
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39. [PubMed]
4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500. [PubMed]
5. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103:3669–76. [PubMed]
6. Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21:3616–22. [PubMed]
7. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993) Blood. 2009;114:5136–45. [PubMed]
8. Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol. 2008;8:380–90. [PubMed]
9. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005;23:6306–15. [PubMed]
10. Weng AP, Ferrando AA, Lee W, Morris JPt, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269–71. [PubMed]
11. O’Neil J, Tchinda J, Gutierrez A, Moreau L, Maser RS, Wong KK, et al. Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med. 2007;204:3059–66. [PMC free article] [PubMed]
12. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell. 1991;67:879–88. [PubMed]
13. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol. 2005;5:189–200. [PubMed]
14. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, et al. RNAi screen for rapid therapeutic target identification in leukemia patients. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:8695–700. [PubMed]
15. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature. 2006;441:106–10. [PubMed]
16. Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, et al. IRF4 addiction in multiple myeloma. Nature. 2008;454:226–31. [PMC free article] [PubMed]
17. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273–87. [PMC free article] [PubMed]
18. Porcu M, Kleppe M, Gianfelici V, Geerdens E, De Keersmaecker K, Tartaglia M, et al. Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood. 2012;119:4476–9. [PubMed]
19. Quintas-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J, et al. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies. Leukemia. 2008;22:1117–24. [PubMed]
20. Wright DD, Sefton BM, Kamps MP. Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia. Mol Cell Biol. 1994;14:2429–37. [PMC free article] [PubMed]
21. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009;114:647–50. [PubMed]
23. [accessed 12/20/2012]; http://browser.1000genomes.org.
24. Hu X, Herrero C, Li WP, Antoniv TT, Falck-Pedersen E, Koch AE, et al. Sensitization of IFN-gamma Jak-STAT signaling during macrophage activation. Nat Immunol. 2002;3:859–66. [PubMed]
25. Shide K, Shimoda K, Kamezaki K, Kakumitsu H, Kumano T, Numata A, et al. Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence. Leuk Res. 2007;31:1077–84. [PubMed]
26. Ihle JN. The Janus protein tyrosine kinases in hematopoietic cytokine signaling. Semin Immunol. 1995;7:247–54. [PubMed]
27. Weber-Nordt RM, Henschler R, Schott E, Wehinger J, Behringer D, Mertelsmann R, et al. Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells. Blood. 1996;88:2549–58. [PubMed]
28. Cohen SB, Crawley JB, Kahan MC, Feldmann M, Foxwell BM. Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology. 1997;92:1–5. [PubMed]
29. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61:5137–44. [PubMed]
30. Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, Cunningham BR, et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002;12:1219–23. [PubMed]
31. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996;379:645–8. [PubMed]
32. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127–32. [PubMed]
33. Porcu M, Gielen O, Cools J, De Keersmaecker K. JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines. Haematologica. 2009;94:435–7. [PubMed]
34. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008;205:751–8. [PMC free article] [PubMed]
35. Asnafi V, Le Noir S, Lhermitte L, Gardin C, Legrand F, Vallantin X, et al. JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study. Br J Haematol. 2010;148:178–9. [PubMed]
36. Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ, et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res. 2008;14:3716–21. [PubMed]
37. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334:1129–33. [PMC free article] [PubMed]
38. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. The Journal of clinical investigation. 2007;117:112–21. [PMC free article] [PubMed]
39. Feng H, Stachura DL, White RM, Gutierrez A, Zhang L, Sanda T, et al. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell. 18:353–66. [PMC free article] [PubMed]
40. Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, Pircher H, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity. 2000;13:549–60. [PubMed]
42. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765. [PubMed]
43. Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity. 2006;25:745–55. [PubMed]
44. Medyouf H, Gao X, Armstrong F, Gusscott S, Liu Q, Gedman AL, et al. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood. 115:1175–84. [PubMed]
45. Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffe M, Mayeux P, et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood. 2000;95:2076–83. [PubMed]
46. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, et al. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A. 2009;106:8695–700. [PubMed]
47. Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, et al. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood. 2008;111:2238–45. [PubMed]
48. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A. 2001;98:31–6. [PubMed]
49. Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006;66:11156–65. [PubMed]
50. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268–74. [PubMed]